Gary Whitlock
Overview
Explore the profile of Gary Whitlock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
4783
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazzitelli M, Krankowska D, Cozzolino C, Scaglione V, Barbaro F, Borgato G, et al.
AIDS
. 2025 Mar;
PMID: 40053508
Objectives: Migrant women (MW) often experience difficulties in accessing sexual healthcare services. We assess the knowledge and acceptability of (Pre-Exposure Prophylaxis) PrEP in MW. Methods: We carried out a survey...
2.
Hanum N, Cambiano V, Sewell J, Rodger A, Asboe D, Whitlock G, et al.
PLoS One
. 2025 Mar;
20(3):e0308238.
PMID: 40036238
The effectiveness of population-level intervention for HIV elimination is influenced by individual-level variation in sexual behaviour. We assess within-person changes in the frequency of condomless anal sex with two or...
3.
Khawaja A, Whitlock G, Fidler S, Soler-Carracedo A, Henderson M, Taylor G, et al.
HIV Res Clin Pract
. 2025 Jan;
26(1):2447015.
PMID: 39763430
Introduction: The BIC-T&T study aimed to determine the efficacy of bictegraviremtricitabine/tenofovir alafenamide (BIC/F/TAF) and darunavir/cobicistat/emtricitabinetenofovir alafenamide (DRV/c/F/TAF) at suppressing viral load in a two-arm, open-label, multi-centre, randomised trial under a...
4.
Whitlock G, Fidler S, Clarke A, Kang S, Xhikola A, Milinkovic A, et al.
HIV Res Clin Pract
. 2024 Sep;
25(1):2400453.
PMID: 39244669
Background: Head-to-head data for bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF; B) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/c/F/TAF; D) are lacking in the context of rapid antiretroviral therapy (ART) initiation. This study, BIC-T&T, evaluates the efficacy...
5.
Nugent D, Apoola A, Coleman H, Gilmour C, Lawton M, Nori A, et al.
Int J STD AIDS
. 2024 Mar;
35(7):498-509.
PMID: 38456387
This guideline offers recommendations on the diagnosis, treatment and health promotion principles needed for the effective management of human papillomavirus (HPV)-related warts at anogenital sites including the external genitals, vagina,...
6.
Spencer M, Patel S, Whitlock G, Mavropoulos I, Mcowan A, Tittle V
Sex Transm Infect
. 2024 Jan;
100(2):122.
PMID: 38195236
No abstract available.
7.
Thornhill J, Fox J, Martin G, Hall R, Lwanga J, Lewis H, et al.
AIDS
. 2023 Dec;
38(5):679-688.
PMID: 38133660
Objective: We present findings from a large cohort of individuals treated during primary HIV infection (PHI) and examine the impact of time from HIV-1 acquisition to antiretroviral therapy (ART) initiation...
8.
Taylor A, Hayes R, Nwokolo N, Whitlock G, Dosekun O, McCormack S, et al.
AIDS Behav
. 2023 Aug;
28(1):274-284.
PMID: 37580575
Oral PrEP's effectiveness relies on adequate adherence during periods of substantial HIV risk. Since most PrEP users will miss doses, understanding predictors within participants can help to explain adherence. We...
9.
Hammond R, Cambiano V, Lampe F, Asboe D, Clarke A, Gilson R, et al.
Sex Transm Infect
. 2023 Jun;
99(7):474-481.
PMID: 37321843
Background: Chemsex (the use of psychoactive drugs in sexual contexts) has been associated with HIV acquisition and other STIs, so there is benefit in identifying those most likely to start...
10.
Whitlock G, Clark J, Tittle V
Lancet HIV
. 2022 Dec;
10(2):e81.
PMID: 36563702
No abstract available.